HK1048253B - 抗腫瘤化合物的口服製劑 - Google Patents

抗腫瘤化合物的口服製劑

Info

Publication number
HK1048253B
HK1048253B HK03100370.7A HK03100370A HK1048253B HK 1048253 B HK1048253 B HK 1048253B HK 03100370 A HK03100370 A HK 03100370A HK 1048253 B HK1048253 B HK 1048253B
Authority
HK
Hong Kong
Prior art keywords
oral formulations
tumor compounds
tumor
compounds
formulations
Prior art date
Application number
HK03100370.7A
Other languages
English (en)
Other versions
HK1048253A1 (en
Inventor
L‧馬格提
A‧馬提尼
P‧西瓦羅裡
C‧詹姆斯
Original Assignee
法瑪西雅意大利公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法瑪西雅意大利公司 filed Critical 法瑪西雅意大利公司
Publication of HK1048253A1 publication Critical patent/HK1048253A1/xx
Publication of HK1048253B publication Critical patent/HK1048253B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100370.7A 1999-10-22 2003-01-15 抗腫瘤化合物的口服製劑 HK1048253B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925127.4A GB9925127D0 (en) 1999-10-22 1999-10-22 Oral formulations for anti-tumor compounds
PCT/EP2000/009647 WO2001030351A1 (en) 1999-10-22 2000-10-02 Oral formulations for anti-tumor compounds

Publications (2)

Publication Number Publication Date
HK1048253A1 HK1048253A1 (en) 2003-03-28
HK1048253B true HK1048253B (zh) 2005-12-02

Family

ID=10863264

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100370.7A HK1048253B (zh) 1999-10-22 2003-01-15 抗腫瘤化合物的口服製劑

Country Status (26)

Country Link
US (1) US7201913B1 (zh)
EP (1) EP1223936A1 (zh)
JP (1) JP2003512430A (zh)
KR (1) KR100838097B1 (zh)
CN (1) CN1198616C (zh)
AR (1) AR031834A1 (zh)
AU (1) AU784201B2 (zh)
BR (1) BR0014902A (zh)
CA (1) CA2387648A1 (zh)
CO (1) CO5251471A1 (zh)
CZ (1) CZ20021372A3 (zh)
EA (1) EA008284B1 (zh)
GB (1) GB9925127D0 (zh)
HK (1) HK1048253B (zh)
HU (1) HUP0202850A3 (zh)
IL (2) IL149044A0 (zh)
MX (1) MXPA02003904A (zh)
MY (1) MY138106A (zh)
NO (1) NO322782B1 (zh)
NZ (1) NZ518398A (zh)
PE (1) PE20010809A1 (zh)
PL (1) PL356236A1 (zh)
SK (1) SK5102002A3 (zh)
TW (1) TWI233355B (zh)
WO (1) WO2001030351A1 (zh)
ZA (1) ZA200203042B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062235A2 (en) * 2000-02-28 2001-08-30 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8541459B2 (en) 2007-01-26 2013-09-24 Pola Pharma Inc. Pharmaceutical composition
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
CN101809024A (zh) * 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
JP2011511071A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 肺癌を治療するためのピコプラチンおよびアムルビシン
HUP0900614A2 (en) * 2009-09-29 2011-05-30 Mate Dr Hidvegi Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production
JP2013512948A (ja) * 2009-12-08 2013-04-18 イル・ファ・カンパニー・リミテッド ２０−Ｏ−β−Ｄ−グルコピラノシル−２０（Ｓ）−プロトパナキサジオールを含む固体分散体
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10143657B2 (en) 2014-01-17 2018-12-04 Oncoral Pharma Aps Solid oral dosage form of irinotecan for the treatment of cancer
CN110448533B (zh) * 2014-12-05 2022-03-29 天津键凯科技有限公司 一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
IL115099A (en) * 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5954998A (en) * 1995-05-25 1999-09-21 The Clorox Company Liquid peracid precursor colloidal dispersions: oil-core vesicles
EP1014953B1 (en) * 1997-03-05 2012-04-25 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
DK0999838T3 (da) * 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
WO2000069434A1 (en) * 1999-05-17 2000-11-23 Ilex Oncology, Inc. Dfmo and celecoxib in combination for cancer chemoprevention and therapy
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules

Also Published As

Publication number Publication date
AR031834A1 (es) 2003-10-08
AU784201B2 (en) 2006-02-23
US7201913B1 (en) 2007-04-10
SK5102002A3 (en) 2002-11-06
IL149044A (en) 2007-03-08
NO20021834L (no) 2002-04-18
CO5251471A1 (es) 2003-02-28
NO322782B1 (no) 2006-12-11
IL149044A0 (en) 2002-11-10
EA008284B1 (ru) 2007-04-27
CN1198616C (zh) 2005-04-27
CA2387648A1 (en) 2001-05-03
ZA200203042B (en) 2003-04-17
GB9925127D0 (en) 1999-12-22
NO20021834D0 (no) 2002-04-18
MXPA02003904A (es) 2003-07-14
HK1048253A1 (en) 2003-03-28
KR20020045613A (ko) 2002-06-19
HUP0202850A3 (en) 2004-12-28
CN1382050A (zh) 2002-11-27
KR100838097B1 (ko) 2008-06-13
TWI233355B (en) 2005-06-01
JP2003512430A (ja) 2003-04-02
PL356236A1 (en) 2004-06-28
NZ518398A (en) 2004-01-30
EP1223936A1 (en) 2002-07-24
PE20010809A1 (es) 2001-08-01
BR0014902A (pt) 2002-06-11
AU7661300A (en) 2001-05-08
HUP0202850A2 (hu) 2003-01-28
MY138106A (en) 2009-04-30
CZ20021372A3 (cs) 2002-09-11
WO2001030351A1 (en) 2001-05-03
EA200200480A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
IL149044A0 (en) Oral formulations for anti-tumor compounds
IL145798A0 (en) Fap-activated anti-tumor compounds
HUP0203204A3 (en) Oral dosage forms
HUP0301349A3 (en) Formulations for il-11
HU9800573D0 (en) Rapamycin formulations for oral administration
AU2564399A (en) Isoflavanoid formulations for oral administration
HUP0003341A3 (en) Rapamycin formulations for oral administration
GB9923045D0 (en) New oral formulations
HK1045102A1 (zh) 藥物配方
GB9817650D0 (en) Oral formulation
EP1210935A4 (en) DRUGS FOR ORAL USE
GB9930578D0 (en) Pharmaceutical formulations
GB9906126D0 (en) Pharmaceutical formulations
AUPP915099A0 (en) Improved composition for oral administration
HK1047232A1 (zh) 口服劑型
SI1216032T1 (sl) Oralne formulacije s kontroliranim sproščanjem
SI1245232T1 (sl) Trdni oralni pripravek
GB9906607D0 (en) Oral composition
GB9925069D0 (en) Oral dosage form
GB9910118D0 (en) Formulations
GB9909079D0 (en) Novel formulations
GB9909080D0 (en) Novel formulations
AU3133900A (en) Improved composition for oral administration
GB9903177D0 (en) Pharmaceutical formulations
GB9905983D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091002